Last reviewed · How we verify
BCG-Russia
BCG-Russia is a Biologic drug developed by Bandim Health Project. It is currently FDA-approved.
BCG-Russia is a vaccine component used in a vaccine, and it is being studied in a clinical trial to evaluate its non-specific effects on infant morbidity and mortality. The trial, NCT03400878, is comparing the effects of two different strains of BCG, including BCG-Russia, on early-life hospital admissions in Guinea-Bissau.
At a glance
| Generic name | BCG-Russia |
|---|---|
| Sponsor | Bandim Health Project |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial to Compare Two Strains of BCG (PHASE4)
- BCG Re-vaccination for Primary Tuberculosis Prophylaxis in the Prison Population (PHASE4)
- Comparing Morbidity and Mortality Effects of Two Different Strains of BCG (PHASE4)
- Trial of Two Strains of BCG (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCG-Russia CI brief — competitive landscape report
- BCG-Russia updates RSS · CI watch RSS
- Bandim Health Project portfolio CI
Frequently asked questions about BCG-Russia
What is BCG-Russia?
Who makes BCG-Russia?
What development phase is BCG-Russia in?
Related
- Manufacturer: Bandim Health Project — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing